Publicacións (25) Publicacións nas que participase algún/ha investigador/a

filter_list Physiology

2025

  1. Meteorin-like protein plasma levels are associated with worse outcomes in de novo heart failure

    European Journal of Clinical Investigation

2023

  1. Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials

    The American journal of cardiology, Vol. 205, pp. 321-324

  2. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension

    European Journal of Heart Failure, Vol. 25, Núm. 7, pp. 936-955

2022

  1. A cost-effectiveness analysis of patiromer for the treatment of hyperkalemia in chronic kidney disease patients with and without heart failure in Spain

    Journal of Medical Economics, Vol. 25, Núm. 1, pp. 640-649

  2. Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases

    Journal of Personalized Medicine, Vol. 12, Núm. 7

2016

  1. Change of concept about the regulation of angiotensin II-induced monocyte chemoattractant protein-1 production in human endothelial cells

    Vascular Pharmacology, Vol. 80, pp. 20-34

2014

  1. Heart mitochondrial proteome study elucidates changes in cardiac energy metabolism and antioxidant PRDX3 in human dilated cardiomyopathy

    PLoS ONE, Vol. 9, Núm. 11

  2. Impaired Adipogenesis and Insulin Resistance in Epicardial Fat-Mesenchymal Cells From Patients With Cardiovascular Disease

    Journal of Cellular Physiology, Vol. 229, Núm. 11, pp. 1722-1730

2013

  1. Benefits of delapril in hypertensive patients along the cardiovascular continuum

    Expert Review of Cardiovascular Therapy, Vol. 11, Núm. 3, pp. 271-281

  2. Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome

    PLoS ONE, Vol. 8, Núm. 9

2012

  1. Baseline epicardial adipose tissue adiponectin levels predict cardiovascular outcomes: A long-term follow-up study

    Cytokine, Vol. 60, Núm. 3, pp. 674-680

  2. Non-genomic vasorelaxant effects of 17Β-estradiol and progesterone in rat aorta are mediated by L-type Ca 2+ current inhibition

    Acta Pharmacologica Sinica, Vol. 33, Núm. 5, pp. 615-624

  3. Variability of NT-proBNP and its relationship with inflammatory status in patients with stable essential hypertension: A 2-year follow-up study

    PLoS ONE, Vol. 7, Núm. 2

2010

  1. Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents

    Cardiovascular Therapeutics, Vol. 28, Núm. 1, pp. 15-22

  2. Erectile dysfunction may improve by blood pressure control in patients with high-risk hypertension

    Postgraduate Medicine, Vol. 122, Núm. 6, pp. 51-56

  3. Proteomic analysis of epicardial and subcutaneous adipose tissue reveals differences in proteins involved in oxidative stress

    American Journal of Physiology - Heart and Circulatory Physiology, Vol. 299, Núm. 1

2009

  1. Inflammatory activation and left ventricular mass in essential hypertension

    American Journal of Hypertension, Vol. 22, Núm. 4, pp. 444-450

2008

  1. Advances in hypertension and diabetes in 2007

    Revista Espanola de Cardiologia, Vol. 61, Núm. SUPPL. 1, pp. 58-71

  2. Epicardial adipose tissue expression of adiponectin is lower in patients with hypertension

    Journal of Human Hypertension, Vol. 22, Núm. 12, pp. 856-863

  3. Use of drugs in the primary prevention of arterial hypertension and dyslipidemia

    Revista Espanola de Cardiologia, Vol. 61, Núm. 8, pp. 861-879